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Post-transplant acute renal failure in cadaver renal recipients treated
with cyclosporine. The outcome of patients with acute renal failure
following cadaveric renal transplant has been evaluated in a prospec-
tive, controlled trial, comparing treatment with cyclosporine (CSA) to
prednisone, azathioprine, and antilymphocyte globulin (AZA). There
was a high incidence of acute post-transplant renal failure in both
groups: 37 of 51 CSA and 31 of 45 AZA patients, due to the long
exposure of kidneys to warm and cold ischemia. Onset of adequate
renal function was delayed for three or more weeks in 27 (53%) CSA
and only nine (20%) AZA patients, and the only predisposing factor
found was donor hypotension. All nine AZA and 18 of the 27 CSA
patients with prolonged oliguria subsequently had a spontaneous
diuresis. Nine of the CSA patients were changed to azathioprine and
prednisone because of suspected CSA toxicity, and eight of these
kidneys began functioning within days, even though they had been
oliguric for 21 to 83 days. Of these nine patients, five had adequate
long-term function on AZA, three developed CMV infections that were
fatal to two individuals, and two rejected their grafts. Plasma CSA
levels fluctuated widely in all patients, but were not higher in any group,
including those with prolonged oliguria. During the oliguric period,
biopsy specimens proved rejection was more common in the nine
patients who had their CSA stopped than in the other CSA patients, and
seven of these nine developed a diffuse interstitial fibrosis that was
thought to be a manifestation of CSA toxicity.
Extensive analysis of the post-transplant course showed rejection
and CSA nephrotoxicity as the only probable causes of the delayed
recovery from oliguria in the CSA group. Although CSA-treated
patients tended to have higher serum creatinines, no significant differ-
ences were found at 12 months in any of the groups. Overall graft
survival was similar in all groups.
Insuffisance rénale aigue post-transplantation chez des receveurs de
rein de cadavre traités par Ia cyclosporine. L'évolution de l'insuffisance
rénale aiguë chez des malades après transplantation de rein de cadavre
a été évaluée par un essai prospectif contrôlé, comparant un traitement
par cyclosporine (CSA) a la prednisone, l'azathioprine, et les globulines
antilymphocytaires (AZA). Ii y a eu une forte incidence d'insuffisance
rénale aiguë post-transplantation dans les deux groupes: 37 malades des
51 CSA et 31 des 45 AZA, en raison de l'exposition prolongée a
l'ischémie chaude et froide. L'apparition d'une fonction rénale correcte
a été retardée de trois semaines ou plus chez 27 (53%) malades CSA et
chez seulement neuf (20%) AZA, et le seul facteur prCdisposant trouvé
a éte l'hypotension du donneur. Les neuf malades AZA et 18 des 27
CSA présentant une oligurie prolongee ant ensuite eu une diurése
spontanée. Neuf des malades CSA ont été changes pour de l'azathio-
prine et de Ia prednisone en raison d'une suspicion de toxicité CSA, et
huit de ces reins ont commence a fonctionner en quelques jours, bien
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qu'ayant été oliguriques pendant 21 to 83 jours. De ces neuf malades,
cinq ant eu une fonction a long terme correcte sous AZA, trois ont
développe des infections a CMV qui ont été fatales chez deux malades,
et deux ant rejecté leur greffon. Les niveaux plasmatiques de CSA ont
largement fluctué chez tous les malades mais n'étaient pas plus élevés
dans un des groupes, y compris ceux avec oligurie prolongée. Pendant
Ia période oligurique, un rejet prouvé par biopsie était plus commun
chez les neuf malades qui avaient eu leur CSA arrêtée, que chez autres
malades CSA, et sept de ces neuf ont developpe une fibrose interstitielle
diffuse qui a été supposée être une manifestation de toxicité de Ia CSA.
Une analyse extensive de l'évolution post-transplantation a identifié
le rejet et Ia nephrotoxicite CSA comme seules causes probables du
retard de recuperation de l'oligurie dans le groupe CSA. Bien que les
malades traités par CSA tendaient a avoir des créatinines seriques plus
élevées, aucune difference n'a été trouvée a 12 mois dans aucun des
groupes. La survie globale du greffons était identique dans tous les
groupes.
The discovery of cyclosporine (CSA), with its unique and
potent immunosuppressive activity [1], has raised expectations
for improved results in all forms of clinical transplantation
[2—6]. Nephrotoxicity is the most important side effect that has
been associated with the use of CSA in humans [2—9], making
its use in renal transplantation somewhat paradoxical. CaIne et
al recommended that renal transplant recipients who do not
achieve an immediate diuresis should not be treated with CSA
[2] and, for this reason, the European Multicentre Study
evaluating the efficacy of CSA has excluded oliguric patients
[3]. Subsequent reports have suggested that CSA can be con-
tinued in patients who do not have immediate onset of renal
function, and that recovery from acute transplant renal failure
will occur even if CSA therapy is continued [4, 10, 11].
We examine herein the early graft function of patients in a
randomized, controlled trial comparing the efficacy of treatment
with CSA alone to a combination of azathioprine, prednisone,
and antilymphocyte globulin (AZA). This study began in 1980
before there was wide experience in the use of CSA, and it was
decided to use CSA both pre- and post-transplant regardless of
early graft function. Because there was little substantial evi-
dence on the reliability of adjusting doses of CSA according to
the blood levels, we used a set dosage regimen, with the aim
that maintaining the dose of CSA would maximize its im-
munosuppressive effect. We monitored plasma CSA levels
prospectively, but did not use them to change CSA dosage.
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Methods
Kidneys for transplant
Cadaver kidneys were obtained through a nationwide trans-
plant exchange program. Recipients were selected on the basis
of HLA B and DR matching and by the presence of a negative
T cell crossmatch on current and peak cytotoxic sera. The
absence of brain death legislation in this state required that
kidneys were removed from the donor only after cardiac arrest,
leading to a period of warm anoxia between the cessation of
respiratory support and cardiac arrest, as well as a period of
warm ischemia between cardiac arrest and flushing with cold
hypertonic citrate perfusion solution. Kidneys were transported
on ice to a central laboratory for machine perfusion as de-
scribed elsewhere [12]. Kidneys not perfused on a machine
were stored on ice and had cold ischemia for at least 20 hr.
Kidneys were kept cool with ice-chilled packs during re-
anastomosis.
Recipient management
A randomized clinical trial began on January 9, 1980, and all
patients entered up until January 9, 1983, are included in this
study. CSA (gift from Sandoz Ltd., North Ryde, Australia) was
begun 2 to 6 hr pre-transplant and continued regardless of early
graft function. The dose schedule was 17 mg/kg body wt/day for
28 days, then reduced by 2 mg/kg body wt/day increments each
7 days until the long-term maintenance dose of 10 mg/kg body
wt/day was reached, 50 days post transplant. CSA was given
orally twice daily, diluted 1 in 10 in pure orange juice.
Rejection episodes were treated with ivi methyl prednisolone
(1,000 mg on Day 1, 500 mg on Day 2, and 250 mg on Day 3),
after which no further steroids were given unless rejection
recurred or persisted. The control group therapy has been
described previously [131.
Pen-operative management of all patients was similar. In
addition to normal fluid management, all patients received
cephamandole nafate (2 g) in the first post-operative day.
Trough CSA serum levels were taken 1 to 3 times a week for
the first 6 weeks after transplantation. Blood collected in EDTA
was taken 12 hr after the dose of CSA, centrifuged immediately
at 4°C, and the separated plasma was stored at —20°C. CSA
levels were measured by HPLC using the method described by
Niederberger, Schaub, and Beveridge [14] and by radio-
immunoassay using the kit supplied by Sandoz (Basel, Switzer-
land) [15].
Needle biopsy specimens were taken from transplant kidneys
every 7 to 10 days during the period of post-transplant oliguria,
unless clinically contraindicated. They were processed and
examined in a semi-quantitative manner by a method described
previously 116].
Analysis of results
Results were analyzed using Student's t test, Mann Whitney
U test and correlation coefficient. P < 0.05 indicates a signifi-
cant difference between groups.
Results
Comparison of the onset of renal function of groups treated
with AZA or GSA
Only 13 of 51 (25%) patients treated with CSA and 14 of 45
(3 1%) of patients treated with conventional therapy had trans-
CSA AZA
Total kidneys used 51 45
Age of donors, years 27 (10 to 62) 25 (7 to 61)
Donors with hypotension requiring
vasoconstrictors 28/47 (59.5%) 22/40 (55%)
Donors with oliguria, < 50 ,nl/hr 3/46 (6.5%) 3/40 (10%)
Serum creatinine of donors,
mole/liter 95 (50 to 165) 100 (65 to 270)
Warm hypoxia, mm 8 (0 to 30) 9 (0 to 30)
Warm ischemia, mm 14 (4 to 35) 13 (0 to 60)
Total warm time, mm 24 (4 to 50) 24 (0 to 90)
Total cold ischemia, hr 22 (13 to 29.2) 24 (16 to 33.5)
Revascularization time, mm 44 (20 to 112) 30 (19 to 65)
Perfused by machine 39/5 1 (76%) 33/45 (73%)
° Data expressed as median (range) or number affected (% affected).
There were no statistically significant differences between any of these
groups.
planted kidneys begin to function within 4 days, without re-
quirement for dialysis post transplant. This immediate function
rate was not significantly different for either group and did not
differ from the 28% achieved in the year prior to the beginning
of this trial. Thus, CSA did not affect the proportion of kidneys
that functioned immediately post transplant.
Of the patients who had no immediate onset of renal function,
nine CSA patients and ten AZA-treated patients lost their grafts
before they recovered from acute post-transplant renal failure.
There were similar causes of these early losses of renal function
in each group, with hyperacute (three CSA and two AZA) and
acute cellular rejection (four CSA and five AZA) being the most
common cause of graft loss. There was one renal artery
thrombosis in each group, one CSA-treated patient's kidney
was removed because of life-threatening hemorrhage after a
needle biopsy, and one AZA patient died of aspergillosis.
Of the grafts that began to function, the onset of adequate
renal function, assessed as the day post transplant that the
serum creatinine fell below 400 imole/liter without dialysis,
was significantly delayed in the CSA-treated group. The median
time in the CSA-treated patients was 25.5 days, with a range of
1 to 98 days, compared to 11.5 days, with a range of 1 to 42
days, in the AZA-treated patients (P < 0.007 with Mann
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Fig. 1. Days post transplant at which there was onset of adequate graft
function, determined by serum creatinine falling to less than 400
moles/liter without dialysis. P < 0.007. Symbols are: CSA
treated; AZA treated.
Table 1. Comparison of donor and preservation data of kidneys used
for transplantation in patients treated with CSA and AZA°
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Table 2A. Outcome of graft function in patients with prolonged post-transplant acute renal failure in whom CSA was ceased
Days from CSA cessation
Until Scr Minimum Rejection
Days on Until <400 Scr on after Complications at change
CSA therapy diuresis moles/liter mo1eIliter CSA CSA of therapy Long-term graft function
82 1 16 145 5 0 Mild CMV Good; 3 years
58 2 19 180 5 0 None Moderate; 2 years
57 2 18 280 9 4 Vascular rejection Nephrectomy at 2 months
72 1 8 325 5 0 Severe CMV, interstitial Graft functioning for 2 weeks;
pneumonitis, colitis then death by CMV
58 2 12 300 5 5 None Moderate; 18 months. Recur-
rence of focal sclerosis
33 1 10 75 2 2 None Good; 1 year
35 6 34 155 0 5 Sepsis, CMV Died septicemia; I month
30 7 13 140 2 1 None Good; 6 months
21 Non-function On dialysis — 2 0 Acute rejection Nephrectomy at 1 month
Abbreviations are: Scr, serum creatinine levels; CMV, cytomegalovirus infection.
Table 2B. Trough plasma CSA in patients with prolonged oliguria that resolved after cessation of CSA therapy
CSA plasma levels, ng/ml
HPLC RIA
Days on CSA therapy Median Range N> 400 Total Median Range N > 400 Total
82 80 0to350 0 28 ND
58 60 0 to 370 0 28 220 0 to 411 2 16
57 90 0 to 220 0 17 189 0 to 347 0 17
72 70 Oto 255 0 52 238 Oto 1900 11 51
58 205 0 to 1450 1 19 375 112 to 1206 10 20
33 35 0 to 55 0 6 39 0 to 66 0 6
35 ND ND
30 ND ND
21 ND ND
Abbreviations: N, number of estimations; ND, not done.
Whitney U test, Fig. 1). Comparison of the details of the kidney
donor, kidney preservation data (Table 1), and tissue matching
(data not shown) for the CSA and AZA treatment groups
revealed no differences. Donor age, hypotension, or oliguria did
not account for the longer period of acute post-transplant renal
failure in CSA-treated patients. All kidneys had a period of
warm hypoxia or ischemia. The length of warm hypoxia, warm
and cold ischemia, and revascularization did not correlate with
the length of post-transplant acute renal failure. The majority of
kidneys were maintained on machine perfusion. There was a
similar high incidence of acute post-transplant renal failure in
patients of both groups receiving kidneys that had or had not
been placed on a perfusion machine.
In the CSA group, there were nine patients with prolonged
oliguria who had their CSA treatment changed to azathioprine
and prednisone because nephrotoxicity was thought to be
contributing to their oliguria. Eight of the nine kidneys began to
function 1 to 9 days after cessation of CSA, no longer requiring
dialysis (Table 2A). The other patient had severe acute rejection
at the time of change, which progressed so that the patient
required nephrectomy. Two patients died with septicemia,
pneumonitis, and colitis caused by severe CMV infection, and
another had an episode of CMV infection within days of
change. Yet another had a severe CMV infection with fever,
arthralgia, dermatitis, and hepatitis, but recovered. Of the
seven surviving patients, four had moderate or severe rejection
episodes within 2 weeks and two of these lost their grafts. Four
patients' grafts continue to have good function (serum creati-
nine (Sr) 75 to 180 moles/liter), and one has mild impaired
function due to recurrence of focal glomerulosclerosis (serum
creatinine 210 jtmoles/liter).
CSA patients with prolonged post-transplant oliguria:
comparison of groups who recovered with and without
cessation of CSA
Clinical data on the donor and kidney preservation that may
have contributed to the prolonged oliguria were compared
(Table 3). The only factor identified to have an effect was
kidney donor hypotension requiring vasoconstrictors to main-
tain blood pressure. Only one of the recipients with immediate
onset of renal function had a kidney from a donor who had been
hypotensive. This contrasted with the very high incidence of
hypotension in kidney donors of patients with prolonged
oliguria (Table 3). No donors had hypotension (systolic BP < 70
mm Hg) for longer than 30 mm. Donors with hypotension had
been stabilized with a variety of vasoconstrictors, including
dopamine, noradrenaline, isoprenaline, and metaraminol. Sim-
ilar periods of hypotension and vasoconstrictor treatment were
experienced by donors whose kidneys did or did not start while
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Table 3. Comparison of donor and preservation data on kidneys used for transplantation in CSA patients with different times
of onset of renal functiona
Onset of renal function
Early
(1 to 7 days)
After 21
days on CSA
After 21 days and
cessation of CSA
Number of patients 10 18 9
Age of donor, years 34.5 (20 to 59) 23.5(7 to 42) 22(14 to 49)
Donors with hypotension requiring
vasoconstrictor treatment 1 (10%) 12 (67%)b 8 (89%)b
Warm hypoxia, mm 13 (3 to 25) 6 (0 to 26) 9 (0 to 29)
Warm ischemia, mm 20 (6 to 38) 14 (4 to 32) 12 (4 to 25)
Total warm time, mm 33 (16 to 44) 21(7 to 50) 21(10 to 38)
Cold ischemia, hr 23 (13 to 28) 21(17 to 28) 26.5 (19 to 29)
Revascularization, mm 40 (25 to 65) 30 (25 to 61) 30 (30 to 52)
Perfused by machine 10 (100%) 12 (67%) 5 (56%)
a Data expressed as median (range) or number affected (% of total).
Significantly different from groups with early function P < 0.01.
All other data groups had no significant differences.
Table 4. Trough plasma cyclosporine (nglm() in patients with prolonged oliguria that resolved without change in cyclosporine therapy
Days until
Scr < 400
zmoles/liter
Rejection episodes during
period of poor function
HPLC RIA
Median Range Number> 400 Total Median Range Number> 400 Total
21 0 250 70 to 540 6 26 290 110 to 857 3 9
21 0 60 0 to 230 0 16 264 51 to 696 6 16
22 0 339 37 to 670 8 26 350 110 to 770 8 19
26 0 230 0 to 500 1 10 225 170 to 320 0 4
33 1 130 50 to 380 0 22 185 65 to 349 0 13
29 0 60 0 to 690 1 25 72 10 to 877 3 13
30 3 80 0 to 340 0 23 215 30 to 1160 14 22
30 4 225 0 to 1270 7 29 369 151 to 895 19 32
30 1 165 0 to 325 0 10 174 90 to 451 2 10
25 2 48 0 to 620 1 12 204 76 to 742 1 12
34 2 190 Oto 565 8 30 293 6Oto 1170 12 30
38 2 250 190 to 440 2 20 340 Oto 1432 6 11
42 0 215 0 to 880 3 30 180 50 to 675 2 17
75 5 48 0 to 620 1 12 204 76 to 742 1 12
50 4 0 0 to 305 0 16 121 74 to 262 0 16
42 2 0 0 to 630 1 19 120 0 to 570 2 19
69 5 205 Oto 1450 10 19 415 112 to 1471 11 20
on CSA. Only one kidney donor for each group had been
oliguric, with a urine output of < 50 mI/hr. Length of the
kidneys' exposure to ischemia, machine perfusion, HLA com-
patibility, and other donor parameters were not different for the
group with early onset of function compared to the group with
prolonged post-transplant renal failure (Table 3).
The post-operative course in patients with prolonged post-
transplant oliguria was examined. The dose of CSA given to all
patients was 17 mg/kg body wt/day for the first 28 days, after
which there was a reduction to 10 mg/kg body wt/day by 50 days
post transplant. No patients with spontaneous onset of renal
function were given doses lower than 10 mg/kg body wt/day. Of
the nine CSA-treated patients switched to AZA treatment, the
first three had their dose reduced to 5 mg/kg body wt/day for 5
to 10 days prior to change, but in no case did such a reduction
lead to resolution of acute renal failure. Trough CSA plasma
levels were measured on all patients up until February, 1983,
but levels of CSA were not used to alter doses. Samples were
assayed by both HPLC and RIA, and there was good correla-
tion between measurements. RIA tended to show higher levels
than HPLC, which probably reflects the fact that it measures
metabolites as well as the CSA molecule, in contrast to the
specific measurement of CSA by HPLC (Tables 2B, 4, and 5).
In the first few days after transplantation, CSA levels were low
or undetectable in nearly all patients. After this period, there
was a wide fluctuation in CSA levels in individual patients with
immediate function, as well as those with prolonged post-
transplant acute renal failure, whether or not they required CSA
to be ceased (Tables 2B, 4, and 5). There was no significant
difference in the range of median and maximum levels recorded
on each patient in the groups. Some patients in all categories
had levels > 400 ng!ml, which may be associated with
nephrotoxicity [17]. The majority of patients with prolonged
oliguria who required cessation of CSA never had levels > 400
nglml, and thus would not have benefited from dose reduction if
levels had been changed. The frequency of levels > 400 ng/ml
was not greater in the patients with prolonged oliguria who
required cessation of CSA than in other patients. Both HPLC
and RIA measurements, > 400 ng/ml, were recorded more
frequently in the CSA patients with prolonged oliguria who
recovered while on CSA therapy than in other patients receiv-
ing CSA (Table 5). No ready explanation for this observation
can be given. In individual patients, the measurement of CSA
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Table 5. Trough cyclosporine A levels (ng/ml) in first six weeks after renal transplantationa
Onset of renal function Within 7 days After 21 days on CSA
After 21 days
and cessation of CSA
HPLC Measurement
Number of patients studied 9 17 6
Measurements/patients 20 (10 to 47) 20 (10 to 30) 19 (6 to 52)
Median levels' 70 (40 to 295) 75 (0 to 339) 165 (72 to 415)
Maximum levelsb 520 (215 to 2240) 303 (225 to 1450) 440 (262 to 1471)
Patients, > 400 ng/ml 6/9 (67%) 10/17 (59%) 1/6 (16.7%)
Total measurements, >400 ng/mI 18/161 (l1.24%Y'
RIA Measurement
48/246 (19.5%)d 3/19 (15.8%)
Number of patients studied 7 17 5
Measurements/patients 20 (10 to 45) 16 (4 to 30) 17 (6 to 51)
Median level&' 194 (50 to 360) 215 (72 to 415) 220 (39 to 375)
Maximum level 701 (194 to 2128) 742 (262 to 1471) 411 (66 to 1900)
Patients, > 400 ng/ml 5/7 (71.4%) 14/17 (82.4%) 3/5 (60%)
Total measurements, > 400 ng/mlc 20/117 (17%) 97/205 (47.3%) 23/87 (26.4%)
Data expressed as median (range) or ratio (percentage).
b Because of the wide fluctuation in CSA levels in individual patients, the median and maximum levels for individual patients were used to
compile this data.
Only readings from the patients who had levels > 400 ng/ml were considered.
d Significant difference 2 4.97, P < 0.05.
Significantly higher than both other groups, P < 0.001.
levels appears to be of little benefit in the early months
following transplantation.
The group who required cessation of CSA had significantly
more rejection episodes, manifested by the number of rejection
treatments during the period of oliguria and by the presence of
rejection on biopsy specimens (Table 6). Cellular rejection was
found in 97% of biopsy specimens from patients with prolonged
oliguria who required cessation of CSA, and in only 65% of
those with prolonged oliguria who required no cessation of
CSA. In patients requiring cessation of CSA, the biopsy spec-
imens taken in the first 3 weeks after transplant showed a
predominant acute cellular rejection accompanied by vascular
damage that consisted of mononuclear cellular infiltrate of the
media and adventitia, fibrinoid necrosis of the media, and
intimal proliferation similar to that seen in vascular rejection.
They responded to corticosteroid treatment, and vessels in
subsequent biopsy specimens from these patients did not show
these changes, even though they remained on CSA. Thus,
persistent acute vascular rejection probably did not contribute
to the prolonged oliguria. Seven of the nine patients in whom
CSA was ceased had biopsy specimens that showed a diffuse
interstitial fibrosis surrounding nearly all tubules and glonieruli
in the cortex (Fig. 2). This feature was usually seen in biopsy
specimens taken after 3 weeks. However, the earliest appear-
ance of this interstitial fibrosis was 14 days post transplant.
Progression of this lesion on serial biopsy specimens was the
indication for change to azathioprine and prednisone in two
patients. Patients who did not have interstitial fibrosis included
one person changed to azathioprine and prednisone because of
uncontrolled acute cellular rejection rather than prolonged
oliguria from CSA nephrotoxicity. The second patient was
changed to CSA after 21 days and was the slowest to achieve
onset of diuresis. Her acute renal failure course was no different
than that of many AZA patients, and it is disputable whether
she had CSA nephrotoxicity. The three biopsy specimens with
fibrosis in the group with spontaneous recovery of renal func-
tion were in one patient who had persistent poor renal function
without evidence of cellular or vascular rejection, and was
thought to be due clinically to CSA toxicity.
Exposure to known nephrotoxins, sepsis, or episodes of
hypotension was not different in the two groups of patients with
prolonged oliguria on CSA (Table 6). Five of the nine patients
who required cessation of CSA had renal angiograms to exclude
vascular occlusion. Two angiograms were performed in the first
4 weeks, and the remainder were performed when the oliguria
was well established. None of the 17 patients with prolonged
oliguria whose grafts began to function while on CSA had renal
angiograms (Table 6). Four of the nine patients who required
cessation of CSA were not exposed to any known nephrotoxins
other than CSA. Thus, contribution of other nephrotoxic agents
does not explain why these patients had prolonged oliguria.
Long-term graft function
Twelve months after transplantation, graft survival was sim-
ilar in both treatment groups in that 32 of 51 patients on CSA
and 28 of 45 AZA patients were alive with functioning grafts.
There was no significant difference in renal function between
groups, with serum creatinine of 170 moles/liter (75 to 500) in
those treated initially with CSA and 140 moles/liter (80 to 390)
in AZA patients. There was a tendency for patients on contin-
ued CSA treatment to have higher serum creatinines (180
tmoles/liter (105 to 500) (N24)) than those patients allocated
to AZA treatment of those treated initially with CSA and
changed to azathioprine and prednisone (115 imoles/liter (75 to
210) (N=8)). The latter group of CSA patients changed to
azathioprine and prednisone includes the five patients with
surviving grafts who were changed because of prolonged
oliguria. The other three patients had onset of renal function
while on CSA in 29, 43, and 51 days, but had consistently poor
renal function subsequently. Because of suspected CSA
nephrotoxicity, they were changed to azathioprine and predni-
sone 11, 5, and 10 months after transplantation, respectively.
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Table 6. Clinical course of CSA patients during post-transplant
renal failure
Onset of renal function
After 21 days
on CSA
After 21 days only
after CSA ceased
Number of patients 17 9
Time serum creatinine dropped
to < 400 moIes/liter, days 30 (21 to 75) 72.5 (43 to 98)
Episodes
hypotension
systemic infection
3 (18%)
3 (18%)
4 (44%)
11(11%)
Exposed to nephrotoxin
renal arteriogram
aminoglycosides
cephalosporins
cotrimoxazole
none
0
4 (24%)
4 (24%)
4 (24%)
5 (28%)
5 (56%)b
2 (22%)
2 (22%)
2 (22%)
4 (44%)
Rejection treatments
0 to 1 during renal failure
> 2 during renal failure
0 to 1 during first 3 months
> 2 during first 3 months
10 (59%)
7 (4 1%)
8 (47%)
9 (53%)
1 (l1%)C
8 (89%)C
1(11%)
8 (89%)
Renal biopsies performed in
first 3 months
Total
No rejection
Cellular rejection, mild
Cellular rejection,
moderate/severe
Vascular rejection
Interstitial fibrosis
26
9 (35%)
7 (27%)
10 (38%)
7 (27%)
3 (12%)
33
1 (3%)d
14 (42%)
15 (45%)
12 (36%)
13 (39%)
a Data expressed as median (range) or number affected (percentage).
b Significant difference P < 0.001.
Significant difference P < 0.05.
"Significant difference P < 0.01.
These three patients had biopsy findings of diffuse interstitial
fibrosis without cellular or vascular rejection and, unlike the
patients with prolonged oliguria, cellular rejection, and vascular
changes, was not identified on earlier biopsy specimens. Serum
creatinine fell significantly in all cases: 290 to 155, 310 to 125,
and 370 to 155 tmo1es/1iter, respectively. Seven of the eight
patients changed from CSA to azathioprine and prednisone
continue to have adequate graft function after follow-up of 18 to
48 months with serum creatinine of 160 moles/liter (75 to 165).
The other patient had recurrence of local sclerosing glomerulo-
nephritis and had progressive deterioration in renal function.
Prior to randomization, patients had been allocated into two
groups: first transplants only or second transplants and high-
risk patients. In the first group, 34 patients were entered in each
treatment arm and at 1 year, graft survival was 72% for CSA
and 75% for AZA patients. This graft survival is comparable to
other studies with low-risk patients [3, 4]. In the high-risk
group, only seven of 17 CSA and two of nine AZA patients had
functioning grafts. The high graft losses in the latter group were
due to rejection, which was the cause of graft loss in all but one
CSA patient, who died of infection. This high graft loss with
second transplants, comprising 33% of our CSA patients,
accounts for the lower one-year graft survival in our overall
results, compared to other studies where only 10 to 15% of
patients were second transplants [3, 4].
Twelve months after transplantation, there was no significant
difference between the serum creatinine of CSA patients with
immediate onset of function (205 moles/liter (110 to 320)
(N=6) and those with oliguria of> 21 days with either sponta-
neous onset of renal function (200 moles/liter (105 to 310)
(N= 13) or requiring a change to azathioprine and prednisone
(170 imoles/liter (120 to 210) (N=5). These serum creatinines
were not significantly different to the AZA patients with imme-
diate function (140 smoles/liter (115 to 255) (N=9) or those with
oliguria> 21 days (170 smoles/1iter (120 to 220) (N=7). There
was a trend for some CSA patients to have higher serum
creatinines, probably due to CSA nephrotoxicity. Delayed
onset of function did not lead to worsened long-term graft
function than those with immediate function.
Discussion
In this study, the use of CSA pre transplant did not increase
the incidence of post-transplant renal failure in patients who
had received cadaver kidneys with long periods of warm and
cold ischemia, many of which had been machine perfused.
However, recovery from post-transplant renal failure was
slower in the majority of the CSA-treated patients. The inci-
dence of post-transplant renal failure was higher than in a center
that used kidneys from beating-heart donors [18], but was not
much different from the 52% acute renal failure reported in the
Canadian study [4]. In neither of these studies was there delay
in recovery of acute post-transplant renal failure in CSA-treated
patients. We examined factors that may have explained the
delay in recovery of renal function in our patients, including
kidney donor and preservation factors, occurrence of rejection,
CSA nephrotoxicity, and exposure to other potentially
nephrotoxic factors. With regard to donor factors, the warm
ischemia and anoxia times were longer than those reported in
other studies, and all kidneys had a minimum of 16 hr cold
ischemia. However, the degree of pre-transplant ischemic dam-
age was not greater for kidneys that had delayed recovery of
renal function, compared to those with early onset of function.
Our study did confirm that donor hypotension is an important
factor in predisposition to acute post-transplant renal failure,
particularly if associated with long warm and cold ischemic
times [19—25]. However, donor hypotension did not explain the
delay in recovery of acute renal failure. We were unable to
confirm the findings of the Canadian study that reported that a
re-anastomosis time of over 45 mm and a long perfusion time
were associated with lesser long-term graft survival in patients
treated with CSA than with standard therapy [4].
Post transplant there was little evidence that factors other
than rejection or CSA nephrotoxicity could have contributed to
the delay in recovery of acute renal failure. The distinction
between these two factors is difficult clinically, and the labora-
tory parameters that may assist in deciding the cause of renal
impairment are subject to different interpretations by different
groups.
The discrimination of nephrotoxicity from rejection in
oliguric patients depends upon pathology. To diagnose rejection
in patients with post-transplant acute renal failure, we per-
formed renal biopsies every 7 to 10 days because moderate to
severe cellular rejection can be seen on biopsy specimens in the
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Fig. 2. Photomicrograph of a hematoxylin and eosin-stained section of a renal biopsy from a patient with prolonged post-transplant renal failure
on CSA. Biopsy shows a diffuse interstitial fibrosis surrounding all tubules. There is no mononuclear cell infiltrate or evidence of vascular rejection.
The patient had received CSA for 50 days and there had been no diuresis. Three days after conversion from CSA to azathioprine there was a
diuresis, and the serum creatinine fell spontaneously without need for dialysis. This graft functions 24 months later, and the patient has a serum
creatinine of 175 moles/liter. There have been no episodes of rejection since this biopsy or the change in therapy. (x 50)
absence of the clinical signs of rejection such as fever, graft
tenderness, or swelling. We interpreted the presence of a
mononuclear cell infiltrate, accompanied by tubular damage, as
an indication of acute cellular rejection. Such changes were
treated with corticosteroids and maintenance of CSA doses. In
previous reports on the pathology in CSA-treated renal trans-
plants, we and others [16, 26] confirmed that the pattern of
rejection was identical to that seen in AZA-treated patients.
Silbey et al contradict this view when they reported mild to
moderate cellular infiltration as consistent with toxicity rather
than rejection [27]. This difference in interpretation may explain
why over 90% of our patients were believed to have patholog-
ical evidence of rejection in the first 3 months post transplant,
and only 30% of the Silbey group were considered to have
rejection and 90% were thought to have evidence of
nephrotoxicity. Serial biopsy specimens demonstrated that mild
to moderate cellular infiltration would disappear after cortico-
steroid treatment without a reduction in CSA dose.
The pathological diagnosis of CSA nephrotoxicity remains
controversial. Tubular changes, including the presence of giant
mitochondria, were similar in both AZA and CSA patients with
acute post-transplant renal failure [28]. Vascular changes were
seen in the first 6 weeks after transplantation in many CSA-
treated patients. At the time, these were interpreted as evidence
of vascular rejection, and the patients were treated with corti-
costeroids. Several reports have suggested that these vascular
changes may be a consequence of CSA nephrotoxicity [26, 29].
Although these vascular lesions were not seen in subsequent
biopsy specimens, the diffuse interstitial fibrosis that we attrib-
uted to CSA nephrotoxicity had developed. Our belief that
diffuse interstitial fibrosis is a consequence of nephrotoxicity is
based on the finding that all seven patients with prolonged
oliguria and this lesion experienced the onset of a diuresis
within 48 hr after cessation of CSA. An additional three patients
with established, but poor, renal function on CSA therapy and
with no concomitant rejection identified on biopsy had a dra-
matic improvement in renal function also within several days of
cessation of CSA. Seven of the ten patients we have seen with
interstitial fibrosis have sustained and adequate renal function
for up to 4 years. Follow-up biopsy specimens from three of
these patients show persistent, but reduced, interstitial fibrosis.
We believe that this interstitial fibrosis represents a conse-
quence of nephrotoxicity because it surrounds more than 80%
of all tubules in the cortex and is not patchy like the fibrosis
seen in chronic rejection [16]. In addition, the rapid improve-
ment of renal function with cessation of CSA suggests a toxic
effect rather than rejection. Presumably, these kidneys have an
injury in addition to the fibrosis that cannot be detected by
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routine light microscopy, and this toxicity would explain the
rapid recovery of renal function after cessation of CSA. The
interstitial fIbrosis would not be reversible rapidly, and any
impairment it caused to renal function would not resolve within
days. Even so, the relative contributions of occult CSA
nephrotoxicity, vasculopathy from CSA or rejection, previous
cellular rejection, and acute post-transplant renal failure to the
pathogenesis of the interstitial fibrosis in our patients cannot be
determined. Further support of our view that fibrosis is a
manifestation of CSA nephrotoxicity is provided in the recent
identification of fibrosis in the kidneys of CSA-treated cardiac
allograft recipients, in whom acute renal failure or kidney
rejection could not have contributed to the fibrosis [30].
The value of monitoring CSA levels in the plasma and
adjusting the dose accordingly remains controversial [17,
31—33], and regular monitoring is based on preliminary pharma-
cological studies that suggest levels above 400 ng/ml were
nephrotoxic [17]. Because of the limited data available, we
elected not to use the values to alter our patients' CSA doses.
This study showed that in individuals on a set dose of CSA
there were wide fluctuations in the trough levels of CSA. The
levels recorded in patients with early onset of good renal
function and those with prolonged oliguria were not different. In
fact, the majority of patients with prolonged oliguria whose
renal function improved immediately on cessation of CSA
never had levels above 400 ng/ml. More recently, Kahan et al
[34] have reported that trough CSA levels < 250 ng/ml are
required to avoid CSA toxicity. However, their study reported
only a few levels on a small number of patients, and may have
overlooked the wide day-to-day fluctuation in levels we have
observed. Even this lower threshold CSA level would not have
helped in the management of many of our patients.
Perhaps the most compelling evidence of the limited value of
monitoring CSA levels is that, after the first week, patients in
our study had levels in the therapeutic range, but still had
episodes of rejection. Lowering the doses at this time could
have compounded the problem of rejection. The Canadian and
Minnesota studies [4, 18], which reported less problems with
rejection, used maintenance corticosteroids that may prevent
the mild cellular rejection episodes we observed in patients
treated with CSA alone. In view of negative corticosteroid side
effects and the risk of lymphoma when multiple immunosup-
pressives are used [2], we omitted maintenance corticosteroids
from our protocol. However, the combination of corticoster-
oids with CSA may allow use of lower, and less nephrotoxic,
doses of CSA. These questions may be answered in the ongoing
Canadian trial that is comparing CSA alone with CSA and
steroids.
Our findings suggest that the change from CSA to
azathioprine and prednisone is not without risk. Rejection can
occur shortly after change in therapy, and this complication
resulted in irreversible rejection to two of our patients. Revers-
ible rejection episodes, as well as loss of kidney grafts from
rejection shortly after change from CSA to azathioprine and
prednisone, has been reported by others [35, 36]. Cytomegalo-
virus (CMV) infection occurred in three patients and was fatal
for two. Viral infections at the time of change have been
reported previously also [35, 36]. This complication may be due
to the increased immunosuppression associated with the addi-
tion of azathioprine and prednisone or to the release of a latent
CMV infection. Other investigators have reported a lower
incidence of CMV in CSA patients [37], and this may be
because CSA did not disturb the immune balance that contains
latent CMV infection. Thus, a change in therapy may allow a
latent infection to progress.
Overall graft survival was not different for both treatment
groups, and, with first cadaver transplants, one-year graft
survival was comparable to those reported by others [3, 4].
Renal function in our patients was similar to that reported by
others [3, 4, 18]; for example, in the European Multicentre
study, serum creatinines were reported to be 184 9.5 in CSA
and 169 17.3 moles/liter in AZA patients [3].
This study shows that the majority of CSA patients with
post-transplant renal failure will have onset of renal function
without need for change in therapy. Nevertheless, we lower the
dose of CSA after 21 days of oliguria in the hope that recovery
from acute renal failure will be accelerated. This usually will
occur within 4 weeks of transplant, particularly if rejection does
not intervene. Ideally, cadaver kidneys removed from
hemodynamically stable beating-heart donors that have not
been exposed to prolonged cold ischemia or machine perfusion
should be used for transplantation. The shortage of kidneys
with these ideal characteristics and the growing number of
potential recipients will necessitate the use of kidneys with a
high risk of post-transplant acute renal failure. The use of CSA
in these patients is not precluded, but clinicians who care for
these patients should be aware that some may need a marked
reduction of the CSA dose or will need to change to
azathioprine before a diuresis will occur. Current lower dose
schedules may reduce the incidence of prolonged oliguria;
however, our findings do not suggest that dose adjustment
according to plasma levels of CSA would have prevented all the
nephrotoxicity we observed and that trough plasma CSA levels
< 250 mg/ml do not preclude CSA nephrotoxicity as a factor
that prolongs the oliguric state.
Oliguria that persists for greater than 3 weeks, particularly if
accompanied by diffuse interstitial fibrosis without ongoing
rejection, may indicate a need for a marked reduction in CSA
dose or a change in therapy since spontaneous recovery of renal
function with continued use of high doses of CSA is unlikely.
Even though long-term renal function does not appear to be
impaired markedly by prolonged post-transplant renal failure,
the changeover period is not without risk since graft rejection
and viral infection complications may occur at this time.
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